(GenomeWeb) – Illumina announced today that it has acquired Australian HLA typing solutions provider Conexio Genomics.
Terms of the deal were not disclosed.
Illumina first partnered with Conexio in March 2015 to offer the TruSight HLA Solution, a sequencing-based product for accurate HLA typing across thousands of known and novel HLA alleles. The product uses Conexio’s Assign software for analysis and reporting.
The acquisition will enable Illumina to develop NGS-based transplant diagnostics assays, including a new solution for interrogating genomic variants in the gamma genomic block of the major histocompatibility complex, the company said in a statement.
“The addition of Conexio products and people solidify our HLA capabilities and demonstrate Illumina’s ongoing commitment to HLA and ultimately to the field of transplant science,” Alex Lindell, Illumina’s associate director of market development for HLA, said in the statement.
Conexio’s NGS development programs will be folded into Illumina’s existing business units.
The SoundControl hearing aid is priced at $850 and comes with the typical trimmings that accompany consumer electronics, such as a connected smartphone app and a 90-day, risk-free trial.
Designed to be worn overnight, the Acuvue Abiliti orthokeratology lenses are specifically fitted to match each eye based on its unique shape.
Antoine Yver, M.D., is Centessa Pharmaceuticals’ new chief medical officer after helping AstraZeneca develop 11 medicines.